PureTech Health receives FDA orphan drug designation for LYT-200, a potential AML treatment, in a Phase 1B trial.
PureTech Health secures FDA orphan drug designation for LYT-200, a potential novel treatment for acute myeloid leukaemia (AML), with the therapy currently being evaluated in an ongoing Phase 1B clinical trial. LYT-200, a monoclonal antibody targeting Galectin-9, has received the designation, qualifying PureTech for incentives under the Orphan Drug Act, including tax credits for some clinical trials.
March 13, 2024
4 Articles